Comparing 2-hour and 6-hour oxaliplatin infusions for gastrointestinal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial investigates the effects of administering oxaliplatin over two different infusion durations (2 hours vs. 6 hours) in patients with gastrointestinal cancers. The primary objective is to assess the severity of sensory neuropathy using patient-reported outcomes at the start of the fourth treatment cycle. Secondary objectives include evaluating pharmacokinetic parameters and clinical outcomes such as therapy duration and dose adjustments. Patients are randomized into two groups to receive oxaliplatin along with leucovorin and fluorouracil, with the aim of minimizing nerve damage and maintaining chemotherapy efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Confirmed diagnosis of a gastrointestinal cancer
* Plan for 4 or more cycles of FOLFOX6 (fluorouracil \[with leucovorin\] and oxaliplatin) containing chemotherapy
* Histologically confirmed, measurable or evaluable disease. Patients with advanced or metastatic disease should have at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients in the adjuvant treatment setting planned to have \> 4 cycles of FOLFOX-containing chemotherapy are eligible and will be followed per standard of care
* Absolute neutrophil count (ANC) ≥ 1,500/µL (no white blood cell growth factors allowed to meet requirement)
* Platelets ≥ 75,000/µL (may be transfused up to 72 hours prior to day 1 to meet requirement)
* Hemoglobin ≥ 8 g/dL (may be transfused up to 72 hours prior to day 1 to meet requirement)
* Creatinine clearance \> 30 mL/min by Cockcroft-Gault, to preserve similar dosing (85 mg/m²) for analysis
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
* Signed informed consent
* Adequate birth control when appropriate

Exclusion Criteria:

* Any preexisting grade 2 or higher peripheral neuropathy
* Patients currently receiving anticancer therapies or who have received any focal or systemic anticancer therapy within 14days of the start of FOLFOX6
* Known intolerance or hypersensitivity to any agent in FOLFOX6 or concurrent agents
* Patients who have any known severe and/or uncontrolled medical conditions such as:

  * Unstable angina pectoris, symptomatic heart failure; (New York Heart Association class III or IV), myocardial infarction ≤ 6 months prior, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
  * Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, or decompensated liver disease
* Patients with any history of severe hemorrhage requiring ≥ 4 units of packed red blood cells (RBCs) in a 48-hour period
* Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
* Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 14days prior to dosing
* Pregnant or nursing (lactating) women
* Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after. Highly effective contraception methods include combination of any two of the following:

  * Use of oral, injected or implanted hormonal methods of contraception or;
  * Placement of an intrauterine device (IUD) or intrauterine system (IUS);
  * Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;
  * Total abstinence or;
  * Male/female sterilization Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential

Where it's running

• Emory University Hospital Midtown
  Atlanta, Georgia, United States Recruiting
• Emory University Hospital/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting
• Emory Saint Joseph's Hospital
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Olumide B. Gbolahan, MBBS, MSc — Emory University
• Study coordinator: Olumide B. Gbolahan, MBBS, MSc
• Email: ogbolah@emory.edu
• Phone: 404-778-0032

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vasodilator Therapy to Reduce Vascular Side Effects in GI Cancer Patients on Fluoropyrimidines

  This study tests whether vasodilator drugs (isossorbide mononitrate or diltiazem) or placebo can reduce blood vessel toxicity for adults with gastrointestinal cancers treated with fluoropyrimidine chemotherapy.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07456852

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Using fucoidan to prevent fatigue in cancer patients undergoing chemotherapy

  This study tests if a seaweed supplement called fucoidan can help cancer patients undergoing chemotherapy feel less tired.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06855524

• Understanding risk factors and genetic changes in biliary tree cancers

  This study is trying to find out what causes biliary tree cancers and how genetic changes can help doctors understand treatment responses in patients with these cancers.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05179486

• Evaluating portal vein stenting for patients with gastrointestinal cancers and vein narrowing

  This study is testing if putting a stent in the portal vein can help people with gastrointestinal cancers and vein narrowing feel better and improve their quality of life.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04629677

• Collecting data on side effects of proton therapy for cancer treatment

  This study is trying to learn about the side effects that cancer patients experience after receiving proton therapy to help improve future treatments.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT00991094

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.